NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
59923-0604-02 | 59923-0604 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec. 31, 2019 | In Use | |
59923-0703-05 | 59923-0703 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0704-14 | 59923-0704 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0705-05 | 59923-0705 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0706-14 | 59923-0706 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0707-05 | 59923-0707 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0708-14 | 59923-0708 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0709-05 | 59923-0709 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0710-14 | 59923-0710 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0711-05 | 59923-0711 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0712-14 | 59923-0712 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0713-05 | 59923-0713 | temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
60763-0601-13 | 60763-0601 | Mercaptopurine | PURINETHOL | 50.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Jan. 15, 2022 | In Use | |
63539-0284-03 | 63539-0284 | palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
63539-0486-03 | 63539-0486 | palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
67457-0450-10 | 67457-0450 | Cladribine | Cladribine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | June 18, 2014 | Dec. 31, 2022 | No Longer Used |
67457-0452-20 | 67457-0452 | Cytarabine | Cytarabine | 2.0 g/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jan. 31, 2012 | Dec. 31, 2022 | No Longer Used |
69097-0905-67 | 69097-0905 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Sept. 17, 2021 | In Use | |
70710-1726-01 | 70710-1726 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
70710-1726-08 | 70710-1726 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
71288-0127-15 | 71288-0127 | Topotecan Hydrochloride | Topotecan | 4.0 mg/15mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 2, 2019 | In Use | |
71288-0150-95 | 71288-0150 | Docetaxel anhydrous | Docetaxel anhydrous | 20.0 mg/2mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 24, 2018 | In Use | |
71288-0151-95 | 71288-0151 | Docetaxel anhydrous | Docetaxel anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 24, 2018 | In Use | |
71288-0151-96 | 71288-0151 | Docetaxel anhydrous | Docetaxel anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 24, 2018 | In Use | |
72064-0110-30 | 72064-0110 | avapritinib | Ayvakit | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Oral | Jan. 9, 2020 | In Use |
Found 10,000 results in 4 milliseconds — Export these results